Neuronetics Stock Performance
| STIM Stock | USD 3.41 0.21 6.56% |
Neuronetics holds a performance score of 18 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -0.2, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Neuronetics are expected to decrease at a much lower rate. During the bear market, Neuronetics is likely to outperform the market. Use Neuronetics downside variance, as well as the relationship between the accumulation distribution and market facilitation index , to analyze future returns on Neuronetics.
Risk-Adjusted Performance
18 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Neuronetics are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. In spite of very weak forward indicators, Neuronetics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 70.3 M |
Neuronetics |
Neuronetics Relative Risk vs. Return Landscape
If you would invest 109.00 in Neuronetics on November 2, 2024 and sell it today you would earn a total of 232.00 from holding Neuronetics or generate 212.84% return on investment over 90 days. Neuronetics is currently generating 2.4372% in daily expected returns and assumes 10.1711% risk (volatility on return distribution) over the 90 days horizon. In different words, 90% of stocks are less volatile than Neuronetics, and 52% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neuronetics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neuronetics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neuronetics, and traders can use it to determine the average amount a Neuronetics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2396
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | STIM | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 10.17 actual daily | 90 90% of assets are less volatile |
Expected Return
| 2.44 actual daily | 48 52% of assets have higher returns |
Risk-Adjusted Return
| 0.24 actual daily | 18 82% of assets perform better |
Based on monthly moving average Neuronetics is performing at about 18% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neuronetics by adding it to a well-diversified portfolio.
Neuronetics Fundamentals Growth
Neuronetics Stock prices reflect investors' perceptions of the future prospects and financial health of Neuronetics, and Neuronetics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neuronetics Stock performance.
| Return On Equity | -1.0 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (0.45) % | ||||
| Operating Margin | (0.52) % | ||||
| Current Valuation | 205.35 M | ||||
| Shares Outstanding | 55.65 M | ||||
| Price To Book | 18.98 X | ||||
| Price To Sales | 2.63 X | ||||
| Revenue | 71.35 M | ||||
| EBITDA | (22.76 M) | ||||
| Cash And Equivalents | 73.7 M | ||||
| Cash Per Share | 2.71 X | ||||
| Total Debt | 62.47 M | ||||
| Debt To Equity | 0.63 % | ||||
| Book Value Per Share | 1.18 X | ||||
| Cash Flow From Operations | (32.04 M) | ||||
| Earnings Per Share | (1.22) X | ||||
| Total Asset | 115.83 M | ||||
| Retained Earnings | (376.08 M) | ||||
About Neuronetics Performance
By examining Neuronetics' fundamental ratios, stakeholders can obtain critical insights into Neuronetics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Neuronetics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. Neuronetics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 198 people.Things to note about Neuronetics performance evaluation
Checking the ongoing alerts about Neuronetics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neuronetics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neuronetics is way too risky over 90 days horizon | |
| Neuronetics appears to be risky and price may revert if volatility continues | |
| Neuronetics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 71.35 M. Net Loss for the year was (30.19 M) with profit before overhead, payroll, taxes, and interest of 54.7 M. | |
| Neuronetics currently holds about 73.7 M in cash with (32.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.71. |
- Analyzing Neuronetics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neuronetics' stock is overvalued or undervalued compared to its peers.
- Examining Neuronetics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neuronetics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neuronetics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neuronetics' stock. These opinions can provide insight into Neuronetics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Medical Equipment space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuronetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Neuronetics is measured differently than its book value, which is the value of Neuronetics that is recorded on the company's balance sheet. Investors also form their own opinion of Neuronetics' value that differs from its market value or its book value, called intrinsic value, which is Neuronetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuronetics' market value can be influenced by many factors that don't directly affect Neuronetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.